Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ProQR Therapeutics N.V.    PRQR   NL0010872495

PROQR THERAPEUTICS N.V.

(PRQR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/06/2020 07/07/2020 07/08/2020 07/09/2020 07/10/2020 Date
5.52(c) 5.36(c) 5.24(c) 4.98(c) 4.99(c) Last
120 818 117 636 151 014 164 735 129 526 Volume
-3.50% -2.90% -2.24% -4.96% +0.20% Change
More quotes
Financials (USD)
Sales 2020 0,90 M - -
Net income 2020 -69,0 M - -
Net cash position 2020 158 M - -
P/E ratio 2020 -3,71x
Yield 2020 -
Sales 2021 6,96 M - -
Net income 2021 -109 M - -
Net cash position 2021 308 M - -
P/E ratio 2021 -2,72x
Yield 2021 -
Capitalization 250 M 250 M -
EV / Sales 2020 102x
EV / Sales 2021 -8,45x
Nbr of Employees -
Free-Float 91,5%
More Financials
Company
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic... 
More about the company
Surperformance© ratings of ProQR Therapeutics N.V.
Trading Rating : Investor Rating :
More Ratings
Latest news on PROQR THERAPEUTICS N.V.
06/12ProQR Announces Expert Perspectives Conference Call Series
GL
06/08ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the..
GL
05/25ProQR Announces Annual Meeting of Shareholders
GL
05/07ProQR Announces First Quarter 2020 Operating and Financial Results
GL
03/31ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 t..
GL
03/25ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Ushe..
GL
02/26ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Busine..
GL
02/24ProQR to Present at Cowen and Company 40th Annual Health Care Conference
GL
02/06ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Bluepr..
GL
01/30ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
GL
2019ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for ..
GL
2019ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dom..
GL
2019ProQR to Present at Upcoming Scientific Conferences
GL
2019ProQR to Present at Upcoming Investor Conferences
GL
2019ProQR Announces Recent Progress and Financial Results for the Third Quarter o..
GL
More news
News in other languages on PROQR THERAPEUTICS N.V.
06/12ProQR Announces Expert Perspectives Conference Call Series
06/08ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the..
05/25ProQR Announces Annual Meeting of Shareholders
05/07ProQR Announces First Quarter 2020 Operating and Financial Results
03/31ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 t..
More news
Chart PROQR THERAPEUTICS N.V.
Duration : Period :
ProQR Therapeutics N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROQR THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 23,83 $
Last Close Price 4,99 $
Spread / Highest target 561%
Spread / Average Target 378%
Spread / Lowest Target 301%
EPS Revisions
Managers
NameTitle
Daniel Anton de Boer Chief Executive Officer
Domenico Valerio Chairman-Supervisory Board
Smital Shah Chief Financial & Business Officer
David M. Rodman Executive Vice President-Research & Development
Aniz Girach Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROQR THERAPEUTICS N.V.-49.65%250
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955